Evaluation of Some Immunological Parameters in with Men Diabetic Nephropathy

Senan Abd Al-Razaq Al-Haddad

Department of Biology, College of Education for Girls, University of Kufa, Iraq.

Saher Mahmood Jwad *

Department of Biology, College of Education for Girls, University of Kufa, Iraq.

*Author to whom correspondence should be addressed.


Abstract

The Aim: The study aims to the possibility of depending on some immunological criteria (monocyte chemoattractant protein (MCP-1, MCP-3) and interleukin-18).

Study Design: The study is indicators for early diagnosis of diabetic nephropathy in patients with type 2 diabetes and avoiding its development to advanced stages.

Place and Duration of Study: Endocrinology Center / Al-Sadr Medical City and also Al-Manathira General Hospital / Al-Najaf Governorate, their ages ranged between (30- 60) years old, and the study continued for the period from 1/10/2022 to 31/3/2023 after obtaining the consent of the two study groups.

Methodology: The study included the follow-up of (90) men, (30) healthy individuals and (60) patients with type 2 diabetes mellitus to periodic clinical examination ,the estimation of glycosylated hemoglobin ratio (HbA1c) and evaluation of immunological parameters represented in levels of monocyte chemoattractant protein (MCP-1 , MCP-3 ) and interleukin-18 .

Results: The study diagnosed a significant increase (P < 0.05) in glycosylated hemoglobin ratio, monocyte chemoattractant protein MCP-1, MCP-3) and interleukin-18 ,and in contrast to a significant decrease (P < 0.05) in the glomerular filtration rate (GFR) in men with diabetes mellitus type II compared to healthy men.

The study also showed a significant effect (P < 0.05) for the age groups on the glycosylated hemoglobin ratio and monocyte chemoattractant protein (MCP-3), and conversely a significant decline in the glomerular filtration rate (GFR) ,while no significant differences appeared (P > 0.05) in levels of monocyte chemoattractant protein (MCP-1) and interleukin-18. Also, a notable impact (P < 0.05) was observed for the duration of diabetes mellitus on the levels of monocyte chemoattractant protein (MCP-1 , MCP-3 ),whereas no substantial differences appeared (P > 0.05) in levels of glycosylated hemoglobin ratio, glomerular filtration rate (GFR) and interleukin-18.

In addition to the foregoing, the trial recorded a significant influence (P < 0.05) of body mass index on the levels of monocyte chemoattractant protein (MCP-3),while no noticeable differences appeared (P > 0.05)in, the glycosylated hemoglobin ratio , glomerular filtration rate(GFR),and monocyte chemoattractant protein (MCP-1).

Moreover, a significant effect (P < 0.05) for stages of diabetic nephropathy was diagnosed on the glycosylated hemoglobin ratio, monocyte chemoattractant protein (MCP-1, MCP-3), interleukin-18 and glomerular filtration rate (GFR).

Conclusion: It is possible to depend on the increased levels of some immunological indicators especially MCP-1, MCP-3 and interleukin-18 as predictive biomarkers to diagnose the progression to advance stages of the diabetic nephropathy if this coincides with a decrease in the glomerular filtration rate.

Keywords: GFR, Interlink-18, MCP-1, MCP-3, diabetic nephropathy


How to Cite

Al-Haddad, S. A. A.-R., & Jwad, S. M. (2023). Evaluation of Some Immunological Parameters in with Men Diabetic Nephropathy. UTTAR PRADESH JOURNAL OF ZOOLOGY, 44(5), 42–54. https://doi.org/10.56557/upjoz/2023/v44i53441

Downloads

Download data is not yet available.

References

Ning C, Jiao Y, Wang J, Li W, Zhou J, Lee YC, et al. Recent advances in the managements of type 2 diabetes mellitus and natural hypoglycemic substances. Food Sci Hum Wellness. 2022;11(5):1121-33. DOI: 10.1016/j.fshw.2022.04.004

Mallone R, Eizirik DL. Presumption of innocence for beta cells: why are they vulnerable autoimmune targets in type diabetes? Diabetologia. 2020;63(10):1999-2006. DOI: 10.1007/s00125-020-05176-7, PMID 32894310.

Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):6275. DOI: 10.3390/ijms21176275, PMID 32872570.

Anastasiou E, Farmakidis G, Gerede A, Goulis DG, Koukkou K, A, Stefos T. Clinical practice. guidelines on diabetes mellitus and pregnancy: Ι. Pre-existing type 1 and type 2 diabetes mellitus. Hormones. 2020;19(4):593-600.

American Diabetes Association. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes. Diabetes Care, 43(Supplement_1). 2020. 2;2020:S14-31.

Balaji R, Duraisamy R, Kumar MP. Complications of diabetes mellitus: a review. Drug Invent Today. 2019;12(1).

Yadav R. A case study on complication of diabetes nephropathy, neuropathy, retinopathy and diabetic foot ulcer [international journal]. 2019;2(4):99.

Najjar ZSR, Jwad SM, Alkhafaji RS. Evaluation of VDR gene polymorphisms with nephropathy stages in men with type 2 diabetes mellitus. J Cardiovasc Dis Res. 2020;11(4):275-9.

Jwad SM, Fatlawi HY. Diabetic nephropathy and its Effect on the physiological factors of the body. Pharmaceutical and Nanotechnology. 2022;4(1):24-30.

Vaidya SR, Aeddula NR. Chronic renal failure. StatPearls [Internet]; 2021.

Yoshimura T. The production of monocyte chemoattractant protein-1 (MCP-1) /CCL2intumor oenvironments. Cytokine. 2017;98:71-8. DOI: 10.1016/j.cyto.2017.02.001 PMID 28189389.

Blanco-Colio LM, Méndez-Barbero N, Pello Lázaro AM, Aceña Á, Tarín N, Cristóbal C, et al, J.. MCP-1 Predicts recurrent cardiovascular events in patients with persistent inflammation. J Clin Med. 2021; 10(5): 1137:MCP-1.

DOI: 10.3390/jcm10051137 PMID 33803115.

Srivastava SP, Hedayat AF, Kanasaki K, Goodwin JE. microRNA crosstalk affects transitions from epithelial to mesenchyme, endothelial to mesenchyme, and macrophage to mesenchyme in the kidney. Front Pharmacol. 2019;10:904. DOI: 10.3389/fphar.2019.00904 PMID 31474862.

Mahmood AMA, Mahmood SJ. Estimation of the protective efficacy of the alcoholic extract of Lepidium sativum seeds on the level of erythropoietin and some physiological parameters of albino male rats dosed with acetaminophen. Uttar Pradesh J Zool. 2022;43(7):42- 51.

Cavalcante JEA, de Sousa ELH, de Oliveira Rodrigues R, de Almeida Viana G, Duarte Gadelha D, de Carvalho MMD, et al. Interleukin-18 promoter- 137/C polymorphism (rs187238) is associated with biochemical markers of renal function and cardiovascular disease in type 2 diabetes. patients. Clin Biochem. 2020; 80:1-7.

DOI: 10.1016/j.clinbiochem.2020.03.011, PMID 32209332.

Eng E, Quaggin S. Putting it all together: Practical approach to the patient with diabetic kidney disease. In: Diabetes and kidney disease. Springer. 2022;637-59.

Nada AM, Younan MA. Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM. Ther Adv Endocrinol Metab. 2021;12: 2042018821995364 DOI: 10.1177/2042018821995364, PMID 33796252.

Akhter N, Wilson A, Thomas R, Al-Rashed F, Kochumon S, Al-Roub A, et al, S. ROS/TNF-α Crosstalk triggers the expression of IL-8 and MCP-1 in human monocytic THP-1 cells via the NF-κB and ERK1/2 Mediated Signaling. Int J Mol Sci. 2021;22(19):10519. DOI: 10.3390/ijms221910519 PMID 34638857.

Rasoul WMR, Mahmood SJ. Evaluation of the efficacy of Brassica oleracea L. alcoholic extract on the levels of D3 and antioxidants in albino male rats dosed with paracetamol. Uttar Pradesh J Zool. 2022;43(6):72-7.

Hassan AM, Kata FS. The role of the biomarkers interleukin-18 and transforming growth factor-beta-1 in predicting and detecting diabetic nephropathy in patients with type 2 diabetes. J Pharm Neg Results. 2022;243-9.

Hirooka Y, Nozaki Y. Interleukin-18 in inflammatory kidney disease. Front Med (Lausanne). 2021;8:639103.

DOI: 10.3389/fmed.2021.639103 PMID 33732720.

Šečić D, Turohan A, Begić E, Rebić D, Pepić E, Begić Z, et al, J. Serum creatinine versus corrected Cockcroft-Gault Equation according to Poggio reference values in patients with arterial hypertension. Int J Appl Basic Med Res. 2022;12(1): 9-13. DOI: 10.4103/ijabmr.ijabmr_301_21 PMID 35265474.

Wu TE, Su YW, Chen HS. Mean HbA1c and HbA1c variability are associated with differing diabetes- related complications in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2022;192: 110069.

DOI: 10.1016/j.diabres.2022.110069, PMID 36067915.

AL-Fatlawi HY, Jwad DSM. Evaluation of physiological and immunological parameters in men with type 2 diabetic nephropathy. Neuro Quantology. 2022; 20(5):646-57 DOI: 10.14704/nq.2022.20.5.NQ22220

Najjar ZSR, Jwad SM, Alkhafaji RS. Assessment of 1.25 (OH) 2D3 levels and nephropathy stages in adult male patients with type-2 diabetes mellitus. J. Crit Rev. 2020;7(13):1667-74.

Flier JS. Starvation in the midst of plenty: reflections on the history and biology of insulin and leptin. Endocr Rev. 2019; 40(1):1-16. DOI: 10.1210/er.2018-00179 PMID 30357355.

Mimenza-Alvarado AJ, Jiménez-Castillo GA, Yeverino-Castro SG, Barragán-Berlanga AJ, Pérez-Zepeda MU, Ávila-Funes JA, et al. Effect of poor glycemic control on cognitive performance in older adults with type 2 diabetes: the Mexican Health and Aging Study. BMC Geriatr. 2020;20(1):1-8.

Liu Z, Dai X, Zhang H, Shi R, Hui Y, Jin X, et al. Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment. Nat Commun. 2020; 11(1):855. DOI: 10.1038/s41467-020-14676-4, PMID 32071312.

Haghighatpanah M, Nejad ASM, Haghighatpanah M, Thunga G, Mallayasamy S. Factors that correlate with poor glycemic control in type 2 diabetes mellitus patients with complications. Osong Public Health Res Perspect. 2018; 9(4):167-74. DOI: 10.24171/j.phrp.2018.9.4.05 PMID 30159222.

Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al, C. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21(17):6275. DOI: 10.3390/ijms21176275, PMID 32872570.

Boye KS, Lage MJ, Shinde S, Thieu V, Bae JP. Trends in HbA1c and body mass index among individuals with type 2 diabetes: evidence from a US database 2012-2019. Diabetes Ther. 2021; 12(7):2077-87. DOI: 10.1007/s13300-021-01084-0 PMID 34076849.

Mahmood N. A, Nemah SM. Chemo – spectral and biological studying of new ligands, research journal of pharmaceutical, biological and chemical sciences. RJPBCS. 2017;8(3):674.

Wondmkun YT. Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications. Diabetes Metab Syndr Obes. 2020;13:3611-6. DOI: 10.2147/DMSO.S275898 PMID 33116712.

Atkin SL, Butler AE, Hunt SC, Kilpatrick ES. The retinopathy‐derived HbA1c threshold of 6.5% for type 2diabetes also captures the risk of diabetic nephropathy in HANES. Diabetes Obes Metab. 2021; 23(9):2109-15. DOI: 10.1111/dom.14449 PMID 34033191.

Natesan V, Kim SJ. Diabetic nephropathy– A review of risk. Factors, progression, mechanism, and dietary management. Biomol Ther (Seoul). 2021;29(4):365-72. DOI: 10.4062/biomolther.2020.204 PMID 33888647.

Scurt FG, Menne J, Brandt S, Bernhardt A, Mertens PR, Haller H, et al. Monocyte chemoattractant protein‐1 predicts the development of diabetic nephropathy. Diabetes Metab Res Rev. 2022;38(2):e3497. DOI: 10.1002/dmrr.3497, PMID 34541760.

Mahmood NA. Farhan ZM. Egypt J Chem. Anticancer study of innovative macrocyclic formazan compounds from trimethoprim drug. 2023;66:1. DOI:10.21608/EJCHEM.2022.132514.5852

Raina P, Sikka R, Gupta H, Matharoo K, Bali SK, Singh V, et al. Association of eNOS and MCP-1genetic variants with type 2 diabetes and diabetic nephropathy genetics, susceptibility: A Case–Control and Meta-Analysis Study. Biochemical. 2021;59(4):966-96.

Mahmoud AA, Soliman MS, Moustafa A. Evaluation of monocyte chemoattractant protein 1 (MCP-1) as a predictor of complications in type 2 diabetes mellitus in Zagazig University Hospital. Egypt J Hosp Med. 2021;83(1):995-1001. DOI: 10.21608/ejhm.2021.160038

Chi M, Tian Zi, Ma K, Li Y, Wang L, Nasser MI, Liu C. Diseased kidneys: Aging and immune aging. Immunity and Aging. 2022;19(1):1-12.

Sanner H, Schwartz T, Flatø B, Vistnes M, Christensen G, Sjaastad I. Increased levels of eotaxin and MCP-1 in juvenile dermatomyositis median 16.8 years after disease onset; associations with disease activity, duration and organ damage. PLOS ONE. 2014;9(3):e92171. DOI: 10.1371/journal.pone.0092171, PMID 24647150.

Wei SY, Pan SY, Li B, Chen YM, Lin SL. Rejuvenation: turning back the clock of aging kidney. J Formos Med Assoc. 2020;119(5):898-906. DOI: 10.1016/j.jfma.2019.05.020 PMID 31202499.

Das R, Lee N, Y, Mukherjee S, Oh S. Relationship of body mass index with diabetes and breast cancer biomarkers. J Diabetes Manag. 2019;9(1):163-8.

Lim JP, Leung BP, Ding YY, Tay L, Ismail NH, Yeo A et al. Monocyte chemoattractant protein-1: A proinflammatory cytokine elevated in sarcopenic obesity. Clin Interv Aging. 2015;10:605-9. DOI: 10.2147/CIA.S78901 PMID 25848236.

Satirapoj B, Dispan R, Radinahamed P, Kitiyakara C. Urinary epidermal growth factor, monocyte chemoattractant protein-1 or their ratio as predictors for rapid loss of renal function in type 2 diabetic patients with diabetic kidney disease. BMC Nephrol. 2018;19(1):246. DOI: 10.1186/s12882-018-1043-x PMID 30241508.

Siddiqui K, Joy SS, George TP, Mujammami M, Alfadda AA. Potential role and excretion level of urinary transferrin, KIM-1, RBP, MCP-1 and NGAL markers in diabetic nephropathy. Diabetes Metab Syndr Obes. 2020;13:5103-11.

DOI: 10.2147/DMSO.S282166 PMID 33408494.

Huang J. Comparing biomarkers for COVID-19 disease with commonly associated preexisting conditions and complications. MedRxiV. 2020;2020-10.

Gonzalez J, Mouttalib S, Delage C, Calise D, Maoret JJ, Pradère JP, et al. Dual effect of chemokine CCL7/MCP-3 in the development of renal tubulointerstitial fibrosis. Biochem Biophys Res Commun. 2013;438(2):257-63.

DOI: 10.1016/j.bbrc.2013.07.025 PMID 23872063.

Larsson A, Carlsson L, Gordh T, Lind AL, Thulin M, Kamali-Moghaddam M. The effects of age and gender on plasma levels of 63 cytokines. J Immunol Methods. 2015;425:58-61 DOI: 10.1016/j.jim.2015.06.009, PMID 26080062.

Kim HO, Kim HS, Youn JC, Shin EC, Park S. Serum cytokine profiles in healthy young and elderly population assessed using multiplexed bead-based immunoassays. J Transl Med. 2011;9(1): 1-7.

Yang C, Jeong S, Ku S, Lee K, Park MH. Use of gasotransmitters for the controlled release of polymer-based nitric oxide carriers in medical applications. J Control Release. 2018;279:157-70. DOI: 10.1016/j.jconrel.2018.04.025, PMID 29673643.

Huber J, Kiefer FW, Zeyda M, Ludvik B, Silberhumer GR, Prager G, et al. CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. J Clin Endocrinol Metab. 2008;93(8):3215-21. DOI: 10.1210/jc.2007-2630, PMID 18492752.

Gilbert RE. Proximal tubulopathy: prime mover and key therapeutic target in diabetic kidney disease. Diabetes. 2017;66(4):791-800. DOI: 10.2337/db16-0796, PMID 28325740.

Suri S, Mitra P, Abhilasha A, Saxena I, Garg MK, Bohra GK, et al. Role of interleukin-2 and interleukin-18 in newly diagnosed type 2 diabetes mellitus. J Basic Clin Physiol Pharmacol. 2021;33(2): 185-90. DOI: 10.1515/jbcpp-2020-0272, PMID 33711216.

Zheng H, Cao JJ. Angiotensin-converting enzyme gene polymorphism and severe lung injury in patients with disease 2019. Am J Pathol. 2020;190(10):2013-7. DOI: 10.1016/j.ajpath.2020.07.009, PMID 32735889.

Qin Z, Li H, Jiao P, Jiang L, Geng J, Yang Q, et al, B. The value of urinary interleukin-18 in predicting acute kidney injury: a systematic review and meta-analysis. Ren Fail. 2022;44(1):1717-31. DOI: 10.1080/0886022X.2022.2133728, PMID 36259446.

Mir M, Rostami A, Hormozi M. Comparison of serum levels of IL-18 in peripheral blood of patients with type II diabetes with nephropathy clinical protests and patients with type II diabetes without nephropathy clinical protests. Diabetes Metab Syndr. 2017;11(4):245-50. DOI: 10.1016/j.dsx.2016.08.018, PMID 27663212.

Zaharieva E, Kamenov Z, Velikova T, Tsakova A, El-Darawish Y, Okamura H. Interleukin-18 serum level is elevated in type 2 diabetes and latent autoimmune diabetes. Endocr Connect. 2018;7(1):179-85. DOI: 10.1530/EC-17-0273, PMID 29217651.

Yasuda K, Nakanishi K, Tsutsui H. Interleukin-18 in health and disease. Int J Mol Sci. 2019;20(3):649.

DOI: 10.3390/ijms20030649, PMID 30717382.

Hrp RSA, nst, AT, Ganie RA. Differences in interleukin 18 levels in diabetic nephropathy and non-diabetic nephropathy patients; 2020.

Sun YM, Su Y, Li J, Wang LF. Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun. 2013;433(4):359-61. DOI: 10.1016/j.bbrc.2013.02.120, PMID 23541575.

Carrara F, Ruggenenti P, Perna A, Iliev IP, Gaspari F, Ferrari S, Parvanova A. Glomerular resistances predict. Decreased long-term glomerular filtration rate in patients with type 2 diabetes without overt nephropathy: A longitudinal subgroup analysis of the DEMAND trial. Acta Diabetol. 2022;59(3):309-17.

AL- Fatlawi HY, Jwad SM. Uttar Pradesh J Zool. Assessing the level of a trial natriuretic peptide and some biochemical parameters in men with type 2 diabetic nephropathy. 2022;43(9):1-13.

Radcliffe NJ, Seah JM, Clarke M, MacIsaac RJ, Jerums G, Ekinci EI. Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig. 2017;8(1):6-18. DOI: 10.1111/jdi.12533, PMID 27181363.

Delanaye P, Jager KJ, Bökenkamp A, Christensson A, Dubourg L, Eriksen BO et al. CKD: A call for an age-adapted definition. J Am Soc Nephrol. 2019;30(10):1785-805. DOI: 10.1681/ASN.2019030238, PMID 31506289.

Szczepanska-Sadowska E, Czarzasta K, Cudnoch-Jedrzejewska A. Dysregulation of the renin-angiotensin system and vasopressinergic system interactions in cardiovascular disorder. Curr Hypertens Rep. 2018;20:1.

Nata N, Rangsin R, Supasyndh O, Satirapoj B. Impaired glomerular filtration rate in type 2 diabetes mellitus subjects: A Nationwide Cross-Sectional Study in Thailand. J Diabetes Res. 2020;2020:6 353949.

DOI: 10.1155/2020/6353949 PMID 32855974.

de Ponte MC, Cardoso VG, Gonçalves GL, Costa-Pessoa JM, Oliveira-Souza M. Early type 1 diabetes aggravates ischemia/reperfusion-induced acute kidney injury. Sci Rep. 2021;11(1):19028. DOI: 10.1038/s41598-021-97839-7

PMID 34561469.

Zhang Y. Role of follistatin-like 1 (FSTL1) in kidney fibrosis. The Chinese University of Hong Kong. Hong Kong; 2019.

Lo JC, Go AS, Chandra M, Fan D, Kaysen GA. GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD. Am J Kidney Dis. 2007;50(4):552-8. DOI: 10.1053/j.ajkd.2007.07.011

PMID 17900454.